Wei Zhang

List of Publications by Year
in descending order

44 papers	15,139 citations	279798 23 h-index	265206 42 g-index
45 all docs	45 docs citations	45 times ranked	20259 citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	28.9	3,979
2	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
3	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015, 372, 2481-2498.	27.0	2,582
4	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell, 2016, 164, 550-563.	28.9	1,695
5	CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2016, 375, 263-273.	7.2	448
6	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics, Proteomics and Bioinformatics, 2021, 19, 1-12.	6.9	439
7	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Research, 2014, 24, 1765-1773.	5.5	316
8	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell, 2018, 175, 1665-1678.e18.	28.9	250
9	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Reports, 2018, 23, 255-269.e4.	6.4	204
10	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	7.2	194
11	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology, 2016, 5, e1196310.	4.6	176
12	Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro-Oncology, 2012, 14, 1432-1440.	1.2	163
13	Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China. PLoS ONE, 2012, 7, e30339.	2.5	114
14	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. OncoImmunology, 2017, 6, e1328339.	4.6	114
15	A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3538-3543.	7.1	93
16	Wholeâ€genome microRNA expression profiling identifies a 5â€microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer, 2013, 119, 814-824.	4.1	79
17	Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathologica, 2015, 130, 587-597.	7.7	68
18	Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMPâ˜' primary glioblastoma. Cancer Letters, 2013, 328, 120-125.	7.2	61

#	Article	IF	Citations
19	Classification of diffuse lowerâ€grade glioma based on immunological profiling. Molecular Oncology, 2020, 14, 2081-2095.	4.6	48
20	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. Cell Death and Disease, 2018, 9, 1190.	6.3	42
21	Molecular subtyping reveals immune alterations in <scp>IDH</scp> wildâ€type lowerâ€grade diffuse glioma. Journal of Pathology, 2020, 251, 272-283.	4.5	42
22	Identification of high risk anaplastic gliomas by a diagnostic and prognostic signature derived from mRNA expression profiling. Oncotarget, 2015, 6, 36643-36651.	1.8	39
23	Multidimensional analysis of gene expression reveals TGFB1I1-induced EMT contributes to malignant progression of astrocytomas. Oncotarget, 2014, 5, 12593-12606.	1.8	36
24	Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Science, 2022, 113, 756-769.	3.9	29
25	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. Frontiers in Immunology, 2020, 11, 581209.	4.8	26
26	Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy . OncoTargets and Therapy, 2019, Volume 12, 10263-10273.	2.0	25
27	Wholeâ€Genome <scp>mRNA</scp> Expression Profiling Identifies Functional and Prognostic Signatures in Patients with Mesenchymal Glioblastoma Multiforme. CNS Neuroscience and Therapeutics, 2013, 19, 714-720.	3.9	24
28	Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide. Cancers, 2020, 12, 3859.	3.7	20
29	Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma. Frontiers in Immunology, 2020, 11, 580934.	4.8	17
30	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. Scientific Reports, 2020, 10, 16218.	3.3	15
31	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. OncoTargets and Therapy, 2021, Volume 14, 1707-1718.	2.0	12
32	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. International Journal of Molecular Sciences, 2022, 23, 5691.	4.1	11
33	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. Cancer Medicine, 2020, 9, 1955-1965.	2.8	10
34	Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. British Journal of Cancer, 2021, 125, 255-264.	6.4	9
35	A novel DNA repairâ€related nomogram predicts survival in lowâ€grade gliomas. CNS Neuroscience and Therapeutics, 2021, 27, 186-195.	3.9	7
36	Highâ€sensitive clinical diagnostic method for PTPRZ1â€MET and the characteristic protein structure contributing to ligandâ€independent MET activation. CNS Neuroscience and Therapeutics, 2021, 27, 617-628.	3.9	7

#	Article	IF	Citations
37	Integrated analysis of the prognostic and oncogenic roles of OPN3 in human cancers. BMC Cancer, 2022, 22, 187.	2.6	6
38	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. Frontiers in Immunology, 2021, 12, 800928.	4.8	6
39	A novel methylation signature predicts radiotherapy sensitivity in glioma. Scientific Reports, 2020, 10, 20406.	3.3	5
40	Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on Enhancer RNA-Regulated Prognostic Genes. Frontiers in Oncology, 2022, 12, 714338.	2.8	4
41	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. BMC Bioinformatics, 2021, 22, 382.	2.6	3
42	A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of Translational Medicine, 2021, 9, 406-406.	1.7	1
43	Uronic acid metabolic processâ€“related gene expressionâ€“based signature predicts overall survival of glioma. Bioscience Reports, 2021, 41, .	2.4	0
44	Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. Frontiers in Genetics, 2021, 12, 741325.	2.3	0